Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 2049-2056

  Yamaori, Satoshi ^a   Okamoto, Yasuka ^a   Yamamoto, Ikuo ^b   Watanabe, Kazuhito ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLNAPHTHALENE; 2 METHYLNAPHTHALENE; 3 [2 (N,N DIETHYL N METHYLAMMONIUM)ETHYL] 7 METHOXY 4 METHYLCOUMARIN; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 5ALPHA PREGNANE 3,20 DIONE; ACENAPHTHENE DERIVATIVE; ACENAPHTHYLENE; BENZ[A]ANTHRACENE; BENZO[A]PYRENE; CANNABIDIOL; CANNABIDIOL DIMETHYL ETHER; CANNABIDIOL METHYL ETHER; CANNABIDIVARIN; CANNABINOID DERIVATIVE; COUMARIN DERIVATIVE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN O DEMETHYLASE; DRONABINOL; FLUORANTHENE; HYDROXYPROGESTERONE; LIMONENE; NAPHTHALENE; O DEMETHYLASE; OLIVETOL; ORCINOL; PENTYLBENZENE; PHENOL DERIVATIVE; PROGESTERONE; RESORCINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

CANNABIDIOL; CANNABINOIDS; COUMARINS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; OXIDOREDUCTASES, O-DEMETHYLATING; PHARMACOKINETICS; POLYCYCLIC HYDROCARBONS, AROMATIC; QUATERNARY AMMONIUM COMPOUNDS; RECOMBINANT PROTEINS; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROCANNABINOL;

CANNABIS SATIVA;

EID: 80054732392     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041384     Document Type: Article

References (40)

1. Aramaki H, Tomiyasu N, Yoshimura H, and Tsukamoto H (1968) Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull 16:822-826.
2. Ball SE, Ahern D, Scatina J, and Kao J (1997) Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 43:619-626. (Pubitemid 27283571)
3. 1-tetrahydrocannabinol. Drug Metab Dispos 20:241-246.
4. Chauret N, Dobbs B, Lackman RL, Bateman K, Nicoll-Griffith DA, Stresser DM, Ackermann JM, Turner SD, Miller VP, and Crespi CL (2001) The use of 3-[2-(N,N-diethyl-N-methylammonium) ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes. Drug Metab Dispos 29:1196-1200. (Pubitemid 32800230)
5. de Graaf C, Oostenbrink C, Keizers PH, van Vugt-Lussenburg BM, van Waterschoot RA, Tschirret-Guth RA, Commandeur JN, and Vermeulen NP (2007) Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. Curr Drug Metab 8:59-77. (Pubitemid 46043892)
6. ELSohly MA and Slade D (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:539-548.
7. Gohda H, Narimatsu S, Yamamoto I, and Yoshimura H (1990) In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol. Chem Pharm Bull 38:1697-1701. (Pubitemid 20265655)
8. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360.
9. Grov C, Kelly BC, and Parsons JT (2009) Polydrug use among club-going young adults recruited through time-space sampling. Subst Use Misuse 44:848-864.
10. Hall W and Degenhardt L (2009) Adverse health effects of nonmedical cannabis use. Lancet 374:1383-1391.
11. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, and Funae Y (2001) Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142:3901-3908. (Pubitemid 32802662)
12. Huestis MA, Henningfield JE, and Cone EJ (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276-282.
13. Jaeger W, Benet LZ, and Bornheim LM (1996) Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26:275-284. (Pubitemid 26128232)
14. Jiang R, Yamaori S, Takeda S, Yamamoto I, and Watanabe K (2011) Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 89:165-170.
15. Kotsuma M, Hanzawa H, Iwata Y, Takahashi K, and Tokui T (2008) Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos 36:1938-1943.
16. Madeira M, Levine M, Chang TK, Mirfazaelian A, and Bellward GD (2004) The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos 32:460-467. (Pubitemid 38420282)
17. McGinnity DF, Waters NJ, Tucker J, and Riley RJ (2008) Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metab Dispos 36:1126-1134. (Pubitemid 351717471)
18. Mechoulam R, Parker LA, and Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S-19S. (Pubitemid 35205041)
19. 9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209-1217.
20. Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, and Desjardins S (2008) A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 21:494-502.
21. Niwa T, Okada K, Hiroi T, Imaoka S, Narimatsu S, and Funae Y (2008) Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol Pharm Bull 31:348-351. (Pubitemid 351442125)
22. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
23. Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, and Hollister LE (1984) Single dose kinetics of cannabidiol in man, in The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects (Agurell S, Dewey WL, and Willette R eds) pp 219-225, Academic Press, New York.
24. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, and Gillespie HK (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409-416. (Pubitemid 10007024)
25. 9-tetrahydrocannabivarin. Br J Pharmacol 153:199-215.
26. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622. (Pubitemid 43847532)
27. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, and Li C (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292-1300.
28. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
29. Strobl GR, von Kruedener S, Stöckigt J, Guengerich FP, and Wolff T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem 36:1136-1145. (Pubitemid 23159287)
30. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, and Yoshimura H (1995) Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 18:1138-1141.
31. Watanabe K, Motoya E, Matsuzawa N, Funahashi T, Kimura T, Matsunaga T, Arizono K, and Yamamoto I (2005) Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206:471-478. (Pubitemid 39601030)
32. Watanabe K, Yamaori S, Funahashi T, Kimura T, and Yamamoto I (2006) 8-Hydroxycannabinol: a new metabolite of cannabinol formed by human hepatic microsomes. Forensic Toxicol 24:80-82. (Pubitemid 46020951)
33. Watanabe K, Yamaori S, Funahashi T, Kimura T, and Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415-1419. (Pubitemid 46367067)
34. Wu D, Otton SV, Inaba T, Kalow W, and Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53:1605-1612. (Pubitemid 27356089)
35. Wu LT, Schlenger WE, and Galvin DM (2006) Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend 84:102-113. (Pubitemid 44137307)
36. Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, and Watanabe K (2011a) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88:730-736.
37. Yamaori S, Kushihara M, Yamamoto I, and Watanabe K (2010) Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691-1698.
38. Yamaori S, Maeda C, Yamamoto I, and Watanabe K (2011b) Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 29:117-124.
39. Yu A and Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520. (Pubitemid 33000701)
40. Zhou SF, Liu JP, and Lai XS (2009) Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 16:2661-2805.